Viveve Medical, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIVE research report →
Companywww.viveve.com
Viveve Medical, Inc. , together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components.
- CEO
- Martin Kerber
- IPO
- 2010
- Employees
- 47
- HQ
- Englewood, CO, US
Price Chart
Valuation
- Market Cap
- $2.15K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.70
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 9.65%
- Op Margin
- -335.40%
- Net Margin
- -342.78%
- ROE
- -199.88%
- ROIC
- -99.76%
Growth & Income
- Revenue
- $6.43M · 17.28%
- Net Income
- $-22,027,000 · -0.51%
- EPS
- $-2.65 · 84.00%
- Op Income
- $-21,553,000
- FCF YoY
- 16.74%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.72
- Avg Volume
- 2.92K
Get TickerSpark's AI analysis on VIVE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 3, 23 | Basta Steven L | other | 72,000 |
| Jan 3, 23 | Durbin Scott | other | 360,000 |
| Jan 3, 23 | JORN DEBORA | other | 36,000 |
| Jan 3, 23 | Morris Arlene | other | 36,000 |
| Jan 3, 23 | Presnell Sharon Collins | other | 36,000 |
| Jan 3, 23 | Robbins Jim B | other | 57,000 |
| Jan 4, 22 | JORN DEBORA | other | 22,000 |
| Jan 4, 22 | Morris Arlene | other | 22,000 |
| Jan 4, 22 | Presnell Sharon Collins | other | 18,000 |
| Jan 4, 22 | Robbins Jim B | other | 42,000 |
Our VIVE Coverage
We haven't published any research on VIVE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VIVE Report →